Summary:

• The global cell and gene therapy market size reached USD 18.8 Billion in 2023.
• The market is expected to reach USD 60.1 Billion by 2032, exhibiting a growth rate (CAGR) of 15.66% during 2024-2032.
• North America leads the market, accounting for the largest cell and gene therapy market share.
• By the therapy type, the market is divided into cell therapy (stem cell {pluripotent stem cell, cancer stem cell, and adult stem cell} and non-stem cell {T cells, natural killer, and others}) and gene therapy.
• Oncology disorder accounts for the majority of the market share in the indication segment due to the burgeoning prevalence of umpteen cancers, such as prostate, lung, breast, and colorectal cancer.
• Based on the delivery mode, the market is divided into in-vivo and ex-vivo.
• Hospitals holds the largest share in the cell and gene therapy industry.
• Government initiatives supporting the development of advanced healthcare solutions are fueling the growth of the market.
• The expanding applications of cell and gene therapies beyond conventional treatments, including regenerative medicine and immunotherapy, are broadening their scope and driving the market expansion.
• The cell and gene therapy market growth is being driven by strategic alliances and partnerships among industry players, along with rapid technological advancements.

Industry Trends and Drivers:

• Advancements in Biotechnology and Genetic Engineering:

The rapid progress in biotechnology and genetic engineering has catalyzed groundbreaking developments in the cell and gene therapy field. Through sophisticated molecular techniques and innovative research methodologies, scientists have gained profound insights into the intricate mechanisms underlying various diseases. This deeper understanding has enabled the design and development of targeted therapeutic interventions that leverage the body's own cellular and genetic machinery to combat diseases at their roots. From engineering viral vectors for gene delivery to refining cell reprogramming techniques, these advancements have paved the way for highly precise and efficacious therapies with the potential to revolutionize patient care.

• Increasing Prevalence of Chronic Diseases:

The escalating prevalence of chronic diseases, including cancer, genetic disorders, and autoimmune conditions, is a significant driver propelling the growth of the global cell and gene therapy market. With populations aging and lifestyle factors contributing to disease burden, there is a pressing need for more effective and durable treatment options. Cell and gene therapies offer promising avenues for addressing these challenges by providing novel approaches that target the underlying causes of diseases rather than merely managing symptoms. As traditional treatment modalities fall short in addressing the complexities of chronic conditions, the demand for innovative therapeutic solutions continues to rise, driving the adoption of cell and gene therapies across a spectrum of medical indications.

• Increasing Investment in Research and Development:

The surge in investment in research and development (RD) activities by pharmaceutical and biotechnology companies is playing a pivotal role in driving the growth of the global cell and gene therapy market. Recognizing the immense therapeutic potential of these innovative approaches, industry stakeholders are committing substantial resources to advance scientific understanding, refine technological capabilities, and accelerate product development timelines. From early-stage discovery research to late-stage clinical trials, this investment is fueling a pipeline of promising cell and gene therapy candidates across a diverse range of therapeutic areas. Moreover, strategic partnerships and collaborations between industry players, academic institutions, and government agencies are fostering cross-disciplinary synergies, driving innovation, and propelling the translation of scientific discoveries into clinically impactful therapies.

Request for a sample copy of this report: https://www.imarcgroup.com/cell-gene-therapy-market/requestsample

Cell And Gene Therapy Market Report Segmentation:

Breakup By Therapy Type:

• Cell Therapy
  • Stem Cell
    • Pluripotent Stem Cell
    • Cancer Stem Cell
    • Adult Stem Cell
  • Non-Stem Cell
    • T Cells
    • Natural Killer
    • Others
• Gene Therapy

By the therapy type, the market is divided into cell therapy (stem cell {pluripotent stem cell, cancer stem cell, and adult stem cell} and non-stem cell {T cells, natural killer, and others}) and gene therapy.

Breakup by Indication:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

Oncology disorders represented the largest segment, primarily because of the pressing need for more effective cancer treatments and the substantial research focus on developing cell and gene therapies targeting various types of cancer, driving the dominance of this indication.

Breakup by Delivery Mode:

• In-Vivo
• Ex-Vivo

Based on the delivery mode, the market is segment into in-vivo and ex-vivo.

Breakup End User:

• Hospitals
• Cancer Care Centers
• Pharmaceutical Biotechnology Companies
• Others

Hospitals represented the largest segment, as they serve as primary centers for patient care, diagnosis, and treatment, making them crucial hubs for administering cell and gene therapies and managing patients with complex medical needs.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America was the largest market, owing to factors such as robust healthcare infrastructure, high investment in research and development, supportive regulatory environment, and early adoption of advanced medical technologies, which collectively propelled the growth of the cell and gene therapy market in this region.

Top Cell And Gene Therapy Market Leaders:

The cell and gene therapy market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.

Some of the key players in the market are:

• Amgen Inc.
• Biogen
• Bluebird bio, Inc.
• Bristol-Myers Squibb
• Gilead Science
• Kolon TissueGene Inc.
• Orchard Therapeutics plc.
• Pfizer Inc
• Renova Therapeutics
• Spark Therapeutics, Inc

Browse full report with TOC List of Figures: https://www.imarcgroup.com/cell-gene-therapy-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145